News

In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $116.35, a high estimate of $168.00, and a low estimate of $75.00.
Blueprint Medicines will receive $775 million in upfront payments, including a cash payment of $675 million and an equity investment by Roche of $100 million in Blueprint Medicines' common stock ...
Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year.
Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter: These 10 analysts have an average price target of $69.0 versus the current price of ...
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The ...
Blueprint Medicines' R&D spending was $110.1 million in Q2, or 191.15% of total revenue, which is exceptionally high in the pharmaceutical industry during a period of higher interest rates.
Blueprint Medicines Corp has a consensus price target of $121.29 based on the ratings of 27 analysts. The high is $168 issued by Goldman Sachs on May 6, 2024. The low is $43 issued by SVB Leerink ...
Blueprint Medicines boosts 2025 revenue guidance to $700M-$720M, driven by AYVAKIT growth & pipeline advancements.
Blueprint Medicines will host the third event in its scientific seminar series, focused on mast cell activation syndrome (MCAS), on Wednesday, June 4, 2025 at 1:00 p.m. ET.
The most optimistic Blueprint Medicines analyst has a price target of US$167 per share, while the most pessimistic values it at US$83.00.
Shares of Blueprint Medicines Corporation (BPMC) traded 26% higher in pre-market on Monday after French pharmaceutical company Sanofi (SNY) announced that it would acquire Blueprint in a bid to ...
Shares of Blueprint Medicines (BPMC 0.30%) fell nearly 21% today after the company announced that its lead drug candidate, avapritinib, failed an important late-stage study in gastrointestinal ...